Patients, oncologists, payers, employers, pharmaceutical and biopharmaceutical companies, diagnostics companies, and investors will all realize substantial value from our approach:

Value for Community Oncologists

We are committed to achieving profitable growth by enhancing current referral relationships, recruiting top clinicians, expanding service lines meaningful to patients, and establishing relationships with payers and self-insured employers. We believe we can substantially increase the number of new patients per physician per year while lowering total operational costs. We further believe our approach creates a model offsetting the current losses in drug margin, diagnostic imaging, and radiation oncology. Together with our evidence-based, state-of-the-art clinical decision support system we believe these changes make KEW practices most attractive to partners, payers, employers, and patients.

Value for Payers & Self-Insured Employers

When genetics, evidence and guidelines are used to consistently and precisely diagnose and treat patients, care is appropriate, efficient and most effective. This is the value that current private payer and employer initiatives and healthcare reform are targeting. We anticipate taking a partnered and leadership role in responsibly and effectively bringing these changes to community oncology.

Value for Therapeutics and Diagnostics Partners

The promise of targeted therapeutics, companion diagnostics, and diagnostic panels for patient stratification and therapeutic response monitoring are great, yet the current evidence suggests that adoption is slow and the process is complicated. KEW Group’s Personalized Medicine platform enables appropriate and rapid adoption of new therapies and diagnostics. Our clinical research, data capture and analytics capabilities will speed patient stratification and recruitment, enable more robust assessment of comparative effectiveness, and accelerate insights into the modern practice of oncology..

Value for Investors

Our approach allows us to be profitable from the outset and cash flow positive quickly. We can bring operational efficiencies and revenue enhancements into the existing and emerging reimbursement environment, while we build the capabilities for a full prospective or bundled payment system complemented by our new clinical research and data service lines. Our combination of deep information technology and operational expertise, practical application of genomics and genetics, and clinical leadership support achieves superior health and financial outcomes.